Giuseppe Garcea

ORCID: 0000-0001-9682-1708
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pancreatic and Hepatic Oncology Research
  • Pancreatitis Pathology and Treatment
  • Gallbladder and Bile Duct Disorders
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Liver Disease Diagnosis and Treatment
  • Appendicitis Diagnosis and Management
  • Pediatric Hepatobiliary Diseases and Treatments
  • Colorectal Cancer Treatments and Studies
  • Liver Disease and Transplantation
  • Hernia repair and management
  • COVID-19 and healthcare impacts
  • Pancreatic function and diabetes
  • Organ Transplantation Techniques and Outcomes
  • Neuroendocrine Tumor Research Advances
  • Gastrointestinal disorders and treatments
  • Cardiac, Anesthesia and Surgical Outcomes
  • Colorectal Cancer Screening and Detection
  • Inflammatory Biomarkers in Disease Prognosis
  • Phytochemicals and Antioxidant Activities
  • Cancer, Hypoxia, and Metabolism
  • Intestinal and Peritoneal Adhesions
  • Pelvic and Acetabular Injuries
  • Sepsis Diagnosis and Treatment
  • Cancer, Lipids, and Metabolism

Leicester General Hospital
2012-2024

University Hospitals of Leicester NHS Trust
2014-2024

National Health Service
2023

King Faisal Specialist Hospital & Research Centre
2023

Glenfield Hospital
2003-2023

University of Leicester
2006-2021

Leicester Royal Infirmary
2003-2014

The University of Adelaide
2009-2010

Queen Elizabeth Hospital
2008-2010

Glasgow Royal Infirmary
2009

Curcumin, a constituent of the spice turmeric, has been shown to reduce adenoma burden in rodent models colorectal cancer accompanied by reduction levels oxidative DNA adduct 3-(2-deoxy-beta-di-erythro-pentafuranosyl)-pyr[1,2-alpha]-purin-10(3H)one (M(1)G) and expression enzyme cyclooxygenase-2 (COX-2). We tested hypothesis that pharmacologically active curcumin can be achieved colorectum humans as measured effects on M(1)G COX-2 protein. Patients with ingested capsules (3,600, 1,800, or 450...

10.1158/1055-9965.120.14.1 article EN Cancer Epidemiology Biomarkers & Prevention 2005-01-01

Studies in vitro and animal models of colorectal hepatocellular cancers suggest that curcumin is an effective chemopreventive agent. In this pilot trial, we investigated whether oral administration results concentrations the agent normal malignant human liver tissue, which are sufficient to elicit pharmacological activity. total, 12 patients with hepatic metastases from cancer received 450–3600 mg daily, for 1 week prior surgery. Levels its metabolites were measured by HPLC portal peripheral...

10.1038/sj.bjc.6601623 article EN cc-by-nc-sa British Journal of Cancer 2004-03-01

In vitro and pre-clinical studies have suggested that addition of the diet-derived agent curcumin may provide a suitable adjunct to enhance efficacy chemotherapy in models colorectal cancer. However, majority evidence for this currently derives from established cell lines. Here, we utilised patient-derived liver metastases (CRLM) assess whether added benefit over 5-fluorouracil (5-FU) oxaliplatin (FOLFOX) cancer stem (CSC) models. Combination with FOLFOX was then assessed clinically phase I...

10.1016/j.canlet.2015.05.005 article EN cc-by Cancer Letters 2015-05-12

Silibinin, a flavonolignan from milk thistle, has intestinal cancer chemopreventive efficacy in rodents. It is strong antioxidant and modulates the insulin-like growth factor (IGF) system by increasing circulating levels of IGF-binding protein 3 (IGFBP-3) decreasing IGF-I. Here, hypothesis was tested that administration oral silibinin generates agent human blood colorectal hepatic tissues consistent with pharmacologic activity. Patients confirmed adenocarcinoma received formulated...

10.1158/1078-0432.ccr-05-2724 article EN Clinical Cancer Research 2006-05-01

Abstract Naturally occurring anthocyanins possess colorectal cancer chemopreventive properties in rodent models. We investigated whether mirtocyan, an anthocyanin-rich standardized bilberry extract, causes pharmacodynamic changes consistent with efficacy and generates measurable levels of blood, urine, target tissue. Twenty-five patients scheduled to undergo resection primary tumor or liver metastases received mirtocyan 1.4, 2.8, 5.6 grams (containing 0.5-2.0 anthocyanins) daily for 7 days...

10.1158/1940-6207.capr-08-0201 article EN Cancer Prevention Research 2009-07-01

Colovesical fistulae are well-recognized but relatively uncommon presentation to colorectal surgery. As a result, few centres have sufficient experience in the investigation and surgical treatment of colovesical develop clear protocols its management.This study examines diagnostic pathways 90 consecutive patients with presenting single surgeon, over six-year period. Using findings from this previously published data, authors suggest tentative guidelines for diagnosis management such...

10.1111/j.1463-1318.2005.00928.x article EN Colorectal Disease 2006-01-31

Objectives: This study examined 85 consecutive patients undergoing total pancreatectomy (±islet cell transplant), examining pain relief, insulin requirements, and glycemic control postoperatively. Methods: A prospective database of all for chronic pancreatitis was used to record preoperative postoperative details from 1996 2006. Results: There were 3 deaths (1 islet recipient 2 nonislet patients). The median number acute admissions fell 5 after pancreatectomy, the length stay 6.2 days 3.3...

10.1097/mpa.0b013e3181825c00 article EN Pancreas 2008-12-18

The serine/threonine kinase Nek2 (NIMA-related 2) regulates centrosome separation and mitotic progression, with overexpression causing induction of aneuploidy in vitro. Overexpression may also enable tumour progression through effects upon Akt signalling, cell adhesion markers the Wnt pathway. objective this study was to examine protein expression colorectal cancer (CRC). examined a panel CRC lines using Western blotting immunofluorescence microscopy. beta-catenin were by...

10.1002/jso.23717 article EN Journal of Surgical Oncology 2014-07-16
Coming Soon ...